Filtered By:
Cancer: Oral Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 3769 results found since Jan 2013.

Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain.
CONCLUSION: Pregabalin produced a marked antinociceptive effect in rat models of facial inflammatory pain as well as in facial neuropathic and cancer pain models, suggesting that it may represent an important agent for the clinical control of orofacial pain. PMID: 25347171 [PubMed - in process]
Source: Journal of Orofacial Pain - November 25, 2014 Category: ENT & OMF Tags: J Oral Facial Pain Headache Source Type: research

Patient-Controlled Intravenous Analgesia for Advanced Cancer Patients with Pain: A Retrospective Series Study.
Conclusion: PCIA provided timely, safe, and satisfactory analgesia for advanced cancer patients with pain and may be useful for titration of opioids, management of severe breakthrough pain, and conversion to oral analgesia. There was no significant difference of analgesic effect and side effect among the hydromorphone, sufentanil, and oxycodone. PMID: 29849846 [PubMed - in process]
Source: Pain Research and Management - June 1, 2018 Category: Anesthesiology Authors: Peng Z, Zhang Y, Guo J, Guo X, Feng Z Tags: Pain Res Manag Source Type: research

Prescribing Trends of Palliative Care Team's Use of Dexamethasone for Cancer-Related Pain.
Authors: Barghi K, Edmonds KP, Ajayi TA, Atayee RS Abstract Opioids are first-line therapy for cancer-related pain. In addition, corticosteroids are commonly utilized as adjuvant analgesics for pain and other symptoms in the oncology setting with limited supporting data. A retrospective analysis was conducted evaluating adult hospitalized patients receiving opioids who received once-daily dexamethasone on the recommendation of a specialty palliative care team during their hospitalization from January 1, 2015, to January 1, 2016. Primary end point was to describe prescribing patterns of dexamethasone in this patient...
Source: Journal of Pain and Palliative Care Pharmacotherapy - May 9, 2018 Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research

Role of Oxycodone Hydrochloride in Treating Radiotherapy-Related Pain.
Abstract Radiotherapy is commonly used to treat cancer patients. Besides the curable effect, radiotherapy also could relieve the pain of cancer patients. However, cancer pain is gradually alleviated about two weeks after radiotherapy. In addition, cancer patients who receive radiotherapy may also suffer from pain flare or radiotherapy-induced side effects such as radiation esophagitis, enteritis, and mucositis. Pain control is reported to be inadequate during the whole course of radiotherapy (before, during, and after radiotherapy), and quality of life is seriously affected. Hence, radiotherapy is suggested to be ...
Source: Pain Research and Management - February 25, 2020 Category: Anesthesiology Authors: Wang Y, Xing L Tags: Pain Res Manag Source Type: research

Chinese expert consensus on patient-controlled intravenous analgesia for cancer pain
Zhonghua Yi Xue Za Zhi. 2023 Mar 21;103(11):793-802. doi: 10.3760/cma.j.cn112137-20221105-02319.ABSTRACTPatient-controlled intravenous analgesia (PCIA) is a common form of individualized treatment for cancer pain, and it has the characteristics of rapid onset, stable blood concentration and on-demand administration, which is suitable for patients who fail to take oral medicine or have poor pain control with oral medications. The preferred drugs for PCIA are strong opioids, which can be combined with sedative drugs according to the patient's condition. Dose titration is required prior to administration of PCIA, dynamic pain...
Source: Pain Physician - March 16, 2023 Category: Anesthesiology Authors: Expert Group of Cancer Pain and Palliative Care, Pain Physician Branch of Chinese Medical Doctor Association Cancer Pain Group, Pain Branch of Chinese Medical Association Source Type: research

Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review.
Authors: Kogure T, Sumitani M, Ikegami K, Abe H, Hozumi J, Inoue R, Kawahara K, Yamada Y Abstract Donepezil, an oral acetylcholinesterase inhibitor, is used to treat Alzheimer's disease and reportedly attenuates opioid-induced sedation in patients with cancer pain. Neuropathic pain is often treated with gabapentinoids (pregabalin, gabapentin), but gabapentinoid-induced somnolence sometimes prevents patients from using these agents. We conducted a retrospective chart review of patients with neuropathic pain to examine whether donepezil is useful for gabapentinoid-induced somnolence. We investigated pain severity in ...
Source: Journal of Pain and Palliative Care Pharmacotherapy - March 15, 2017 Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research

Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial.
CONCLUSIONS: Although underpowered, this study demonstrates a clinically important analgesic signal. TTX may provide clinically meaningful analgesia for patients who have persistent moderate to severe cancer pain despite best analgesic care. This clinical study is registered with ClinicalTrials.gov (NCT00725114). PMID: 28555092 [PubMed - in process]
Source: Pain Research and Management - June 1, 2017 Category: Anesthesiology Authors: Hagen NA, Cantin L, Constant J, Haller T, Blaise G, Ong-Lam M, du Souich P, Korz W, Lapointe B Tags: Pain Res Manag Source Type: research

The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain.
We report the successful use of low-dose ketamine infusion for the treatment of opioid-induced hyperalgesia in a 38-year-old woman presenting with psychosocial suffering and high opioid requirement secondary to pain from a poorly differentiated neuroendocrine tumor. Over the course of a month, her opioid requirement escalated to the gram level of oral morphine equivalents, upon which she was hospitalized at University of California San Diego Health for an acute on chronic pain crisis. Despite use of patient-controlled analgesia, her pain level remained unchanged for nearly 2 days after initiation of a low-dose ketamine inf...
Source: Journal of Pain and Palliative Care Pharmacotherapy - May 29, 2019 Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research

Frequency of pain and correlation with clinical and histologic parameters in T1 squamous cell carcinoma of the tongue: a retrospective pilot study.
CONCLUSION: Despite the limited number of cases, the results of this study suggest that painful OSCCs of the tongue may be associated with more intense inflammation. PMID: 24482787 [PubMed - indexed for MEDLINE]
Source: Journal of Orofacial Pain - November 25, 2014 Category: ENT & OMF Tags: J Oral Facial Pain Headache Source Type: research

Case Report: Utility of Ketamine, Lidocaine, and Mexiletine as Nonopioid Adjuvants in Complex Cancer-Associated Pain.
Authors: Hakim RC, Edmonds KP, Atayee RS Abstract Ketamine, lidocaine, and mexiletine are potential nonopioid adjuvant medications for the use of refractory cancer-related pain, particularly when opioids are demonstrating limited objective benefit. This is a case report of a single patient admitted to a large academic medical center in the United States. The patient is a 43-year-old woman with a history of Crohn's disease complicated by rectal squamous cell carcinoma and complex, progressive, and intractable pelvic and rectal pain. Over the course of hospitalization, her pain demonstrated limited opioid responsiven...
Source: Journal of Pain and Palliative Care Pharmacotherapy - May 9, 2018 Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research

Breakthrough cancer pain: twenty-five years of study
Abstract: Breakthrough cancer pain (BTcP) is an episode of severe pain that “breaks through” a period of persistent pain at least partly controlled by a stable opioid regimen. Although mentioned in the literature decades ago, it has been only 25 years since the first effort to define and measure it. Controversy about the definition of BTcP continues despite an international effort to achieve consensus. Nevertheless, common approaches to measurement of BTcP have led to a robust literature, including many surveys that have described prevalence, characteristics, and association with adverse outcomes. Measurement also has ...
Source: Pain - November 22, 2016 Category: Anesthesiology Tags: Pain Classics Source Type: research

A Multi-Centered Case Series Highlighting the Clinical Use and Dosing of Lidocaine and Mexiletine for Refractory Cancer Pain.
Authors: Atayee RS, Naidu D, Geiger-Hayes J, Saphire ML, Hausdorff J, Edmonds KP Abstract Lidocaine infusion for pain control has been used for years. While some centers transition from continuous infusion lidocaine to oral mexiletine, there are no published studies to guide this conversion in pain and palliative care settings. This is a retrospective case series of 10 cancer patients across four institutions, with attention to dosing of both agents, and subsequent decrease in morphine-equivalent daily dosing (MEDD). The mean age was 55 years (range 34-78). The mean bolus dose of lidocaine was 1.6 mg/kg, infuse...
Source: Journal of Pain and Palliative Care Pharmacotherapy - February 25, 2020 Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research

Fentanyl tolerance in the treatment of cancer pain: a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose.
Authors: Sutou I, Nakatani T, Hashimoto T, Saito Y Abstract Opioids are not generally deemed to have an analgesic ceiling effect on cancer pain. However, there have been occasional reports of tolerance to opioid development induced by multiple doses of fentanyl. The authors report a case of suspected tolerance to the analgesic effect of opioid, in which an increasing dose of fentanyl failed to relieve the patient's cancer pain symptoms, but opioid switching to oxycodone injections enabled a dose reduction to below the equivalent dose conversion ratio. The patient was a 60-year-old man diagnosed with pancreatic body...
Source: Journal of Pain and Palliative Care Pharmacotherapy - November 20, 2015 Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research

(305) A novel rodent model for studying mechanisms behind oral cancer pain
Head and neck cancer (HNC) accounts for approximately 3-10% of cancers worldwide, with the majority reporting pain as their top symptom. Patients report severe spontaneous and mechanical pain during eating, chewing, and swallowing. The mechanisms behind HNC pain remains unknown. We hypothesize that human oral squamous carcinoma cells (OSCC) control the activities of nociceptors at the site of the tumor. To test this hypothesis, we developed a preclinical model of HNC pain. Athymic male mice (20g) dorsal tongues were injected with the HSC-2 line of OSCC.
Source: The Journal of Pain - March 31, 2016 Category: Materials Science Authors: L. Chodroff, S. Ruparel, M. Bendele, M. Henry Tags: E02 Animal Models of Cancer Pain Source Type: research